Verona pharma completes enrollment in phase 3 enhance-2 trial evaluating ensifentrine for maintenance treatment of copd

Top-line data expected in the third quarter of 2022 top-line data expected in the third quarter of 2022
VRNA Ratings Summary
VRNA Quant Ranking